Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elan, a neuroscience-based biotechnology company, has announced that it is realigning some of its functions to direct additional investment towards its innovative pipeline.
Subscribe to our email newsletter
The realignment will result in the elimination of a number of positions and additional refinement to Elan’s commercial activities in Tysabri for Crohn’s disease. Elan has also decided to close its offices in New York and Tokyo during the first quarter of 2009.
According to Carlos Paya, president of Elan, the company will shift its effort from what is a traditional sales commercial model to a model based on clinical support and education.
Kelly Martin, CEO of Elan, said: “We continually evaluate our pipeline, product portfolio, and company structure with a goal of maintaining our flexibility and ability to invest in the most valuable product opportunities for patients while driving value for our shareholders.”